ISTH0036

Published

dm+d

Unassigned

New Medicines

Glaucoma; advanced - prevention of scarring in post glaucoma filtration surgery (GFS)

Information

New molecular entity
Isarna Therapeutics
Isarna Therapeutics

Development and Regulatory status

None
Phase I Clinical Trials
None
Yes
Yes

Category

Antisense-oligonucleotide. Transforming growth factor beta2 inhibitors [2]
22 May 2015Glaucoma is common and accounts for 2% of visual impairment and 8% of blindness in the world. In the UK, glaucoma is the second most common cause for registration of visual impairment, accounting for 9-12% of registrations in people over the age of 65 years [3].
Glaucoma; advanced - prevention of scarring in post glaucoma filtration surgery (GFS)
Intravitreal